Innovation & Tech
Moderna’s Cancer Vaccine Breakthrough Validates mRNA Platform as Merck Gains
Moderna and Merck reported the first positive Phase 3 results for an individualized mRNA cancer therapy, sending MRNA stock sharply higher. The melanoma study met key endpoints when Moderna’s intismeran was combined with Merck’s Keytruda.